News articles about CytomX Therapeutics (NASDAQ:CTMX) have trended somewhat positive this week, Accern reports. The research firm scores the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. CytomX Therapeutics earned a news impact score of 0.21 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 45.1347523074408 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

These are some of the news articles that may have effected Accern Sentiment’s scoring:

A number of research firms have recently issued reports on CTMX. BidaskClub lowered shares of CytomX Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, July 24th. Cann reaffirmed a “hold” rating on shares of CytomX Therapeutics in a research report on Tuesday, August 8th. Cowen and Company reaffirmed an “outperform” rating on shares of CytomX Therapeutics in a research report on Thursday. Oppenheimer Holdings, Inc. reaffirmed a “hold” rating on shares of CytomX Therapeutics in a research report on Wednesday. Finally, Bank of America Corporation raised their price objective on shares of CytomX Therapeutics from $30.00 to $34.00 and gave the company a “buy” rating in a research report on Wednesday. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and six have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $32.67.

CytomX Therapeutics (NASDAQ:CTMX) opened at 22.06 on Friday. The company’s 50-day moving average is $17.15 and its 200 day moving average is $15.67. CytomX Therapeutics has a 12 month low of $9.85 and a 12 month high of $24.67. The company’s market cap is $813.29 million.

CytomX Therapeutics (NASDAQ:CTMX) last posted its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.30). CytomX Therapeutics had a negative net margin of 206.33% and a negative return on equity of 84.61%. The business had revenue of $8.75 million during the quarter, compared to the consensus estimate of $4.95 million. Equities analysts forecast that CytomX Therapeutics will post ($1.47) earnings per share for the current fiscal year.

In related news, insider Sean A. Mccarthy sold 4,781 shares of the stock in a transaction on Wednesday, August 9th. The stock was sold at an average price of $15.00, for a total value of $71,715.00. Following the sale, the insider now owns 9,026 shares in the company, valued at approximately $135,390. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, major shareholder Robert I. Tepper sold 20,000 shares of the stock in a transaction on Tuesday, September 19th. The shares were sold at an average price of $18.00, for a total value of $360,000.00. Following the completion of the sale, the insider now owns 54,293 shares in the company, valued at approximately $977,274. The disclosure for this sale can be found here. In the last 90 days, insiders sold 100,306 shares of company stock worth $1,924,746. 4.70% of the stock is owned by company insiders.

WARNING: This piece was first reported by Watch List News and is owned by of Watch List News. If you are reading this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.watchlistnews.com/cytomx-therapeutics-ctmx-receiving-somewhat-favorable-media-coverage-report-finds/1612633.html.

About CytomX Therapeutics

CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.

Insider Buying and Selling by Quarter for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.